. 2013 Dec 11;2(2):201–208. doi: 10.1007/s40121-013-0022-6

Table 1.

Baseline characteristics

Variable	Young (n = 44)	Older adults (n = 44)	Very elderly (n = 44)	p
Age (years)	52 (41–59)	70 (66–75)	87 (82–90)	<0.01
Male sex	21 (48)	19 (43)	20 (46)	0.91
Baseline SCr (mg/dL)	0.86 (0.67–1.2)	1.00 (0.71–1.24)	1.07 (0.96–1.36)	0.01
CrCl (mL/min)	73 (54–92)	45 (37–60)	34 (26–45)	<0.01
Charlson score	1 (0–3)	2 (1–3)	2 (1–3)	0.11
Race
Caucasian	18 (40.9)	11 (25.0)	19 (43.2)	0.11
African American	21 (47.7)	21 (47.7)	22 (50.0)
Hispanic	1 (2.3)	0 (0.0)	0 (0.0)
Asian	1 (2.3)	4 (9.1)	0 (0.0)
Other	3 (6.8)	8 (18.2)	3 (6.8)
Infection site^a
Abdominal	1 (2.3)	3 (6.8)	0 (0.0)	0.16
Blood	11 (25.0)	9 (20.5)	13 (29.5)	0.61
Bone	3 (6.8)	1 (2.3)	1 (2.3)	0.44
Central nervous system	3 (6.8)	0 (0.0)	4 (9.1)	0.14
Genitourinary	2 (4.5)	7 (15.9)	8 (18.2)	0.12
Joint	0 (0)	0 (0)	1 (2.3)	0.36
Lower respiratory tract	13 (29.5)	19 (43.2)	17 (38.6)	0.40
Skin and soft tissue	9 (20.5)	5 (11.4)	5 (11.4)	0.37
Wound	2 (4.5)	0 (0)	0 (0)	0.13
Other	3 (6.8)	2 (4.5)	1 (2.3)	0.59
Goal vancomycin trough 15–20 mg/L	31 (70.5)	30 (68.2)	34 (77.3)	0.61
Length of treatment (days)	7 (5–9)	9 (6–12)	7 (5–10)	0.05
Risk factors for nephrotoxicity
History of AKI or chronic kidney disease	16 (36.4)	16 (36.4)	16 (36.4)	1.00
High-dose vancomycin^b or weight ≥110 kg	1 (2.3)	1 (2.3)	1 (2.3)	1.00
Vasopressors	2 (4.5)	2 (4.5)	2 (4.5)	1.00
Nephrotoxins^c	16 (36.4)	16 (36.4)	1 (36.4)	1.00

Data are median (interquartile range) or n (%)

AKI acute kidney injury, CrCl creatinine clearance, SCr serum creatinine

^aInfection sites are not mutually exclusive

^bAt least 4 g of vancomycin per day

^cAcyclovir, IV aminoglycosides, IV amphotericin B, IV contrast dye, loop diuretics, IV colistin